- Molecular NameBethanidine
- SynonymBetanidin; Betanidine; Bethanidine sulfate
- Weight388.332
- Drugbank_IDDB00217
- ACS_NO55-73-2
- Show 2D model
- LogP (experiment)1.493
- LogP (predicted, AB/LogP v2.0)-5.59
- pka12
- LogD (pH=7, predicted)-10.07
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)2049.01
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond Donors6
- No.of HBond Acceptors10
- No.of Rotatable Bonds4
- TPSA167.4
- StatusFDA approved
- AdministrationN/A
- PharmacologyA sympatholytic drug.
- Absorption_valueN/A
- Absorption (description)Bethanidine is readily but incompletely absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt does not appear to be metabolised.
- Half lifeThe plasma half-life is multiphasic and there is considerable intersubject variation; after intravenous administration, plasma half-lives of about 2 to 6 h and terminal half-lives of several days have been reported.
- ExcretionAfter an IV dose, about 90% is excreted unchanged in the urine in 3 to 4 days; after an oral dose, 50 to 85% is excreted in the urine and up to about 50% is eliminated in the faeces.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A